Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

@article{Fu2011Phase1S,
  title={Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.},
  author={Siqing Fu and W Hu and Revathy B. Iyer and John J. Kavanagh and Robert L Coleman and Charles F. Levenback and Anil K Sood and Judith K. Wolf and David M. Gershenson and Maurie Markman and Bryan T. J. Hennessy and Razelle Kurzrock and Robert C. Bast},
  journal={Cancer},
  year={2011},
  volume={117 8},
  pages={
          1661-9
        }
}
BACKGROUND Sequential treatment with azacitidine can induce re-expression of epigenetically silenced genes through genomic DNA hypomethylation and reverse carboplatin resistance of epithelial ovarian cancer cells. A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. METHODS Patients with pathologically confirmed intermediate-grade or high-grade epithelial… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 76 CITATIONS, ESTIMATED 46% COVERAGE

Neuroendocrine tumours: cracking the epigenetic code.

VIEW 1 EXCERPT
CITES BACKGROUND
HIGHLY INFLUENCED

DNA methylation as a transcriptional regulator of the immune system

DNMT Inhibitors Increase Methylation in the Cancer Genome

VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 7 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 40 REFERENCES

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer

  • PT Ramirez, CN JrLanden, RL Coleman
  • Gynecol Oncol
  • 2008
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Promoter hypermethylation profile of ovarian epithelial neoplasms.

VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

DNA hypomethylation in cancer cells.

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.